Just after posting Genentech’s response to my questions, I received an email from Christopher C. Kelly of the FDA’s Office of Public Affairs informing me that he isn’t able to address my specific questions because they are not considered public information. However, he did provide the following statement:
November 14, 2007
FDA did not ask Genentech to stop distributing Avastin to compounding pharmacies and FDA has not taken action to limit the off-label use of Avastin. FDA has discussed with Genentech developing Avastin for the treatment of macular degeneration and studying its use in ocular indications.